Page 46 - Nsclc News Today

The approval expands the drug label to include a variety of RET-positive tumor types, including pancreatic and colorectal cancers.

"Its very challenging in a rural or small community. I miss the opportunity to elaborate on a case."

Patients with untreated NSCLC who could not withstand the rigors of platinum-based chemotherapy regimens had much better overall survival when treated with the immune checkpoint inhibitor atezolizumab.

A new retrospective analysis suggests small cell lung cancer (SCLC) has a different genomic profile among smokers than nonsmokers.

Researchers have uncovered a potential mechanism whereby the air we breathe may trigger driver mutations already present in normal lung cells to cause cancer.

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced data from a poster presentation titled: High Activity of

Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data, today announced new data showing that the deep learning capabilities of the Nucleai

Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition Corp. and will change its name to Ocean Biomedical, Inc., expected to...

Improving cancer outcomes via improved prevention and early detection and treatment, and better educating oncologists to implement the latest discoveries, will be the focus of the ESMO Congress 2022.

Stereotactic ablative radiotherapy (SABR) is a well-established treatment for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC) and pulmonary oligometastases. The use of single-fraction SABR in this setting is supported by excellent local control and safety profiles which appear equivalent to multi-fraction SABR based on the available data. The resource efficiency and reduction in hospital outpatient visits associated with single-fraction SABR have been particular...